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Abstract: Background: Acute myeloid leukemia is a heterogeneous hematological disease, characterized
by karyotypic and molecular alterations. Mutations in IDH2 have a role in diagnosis and as a minimal
residue disease marker. Often the variant allele frequency during follow up is less than 20%, which
represents the limit of detection of Sanger sequencing. Therefore, the development of sensitive
methodologies to identify IDH2 mutations might help to monitor patients’ response to therapy.
We compared three different methods to identify and monitor IDH2 mutations in patients’ specimens.
Methods: Performances of PNA-PCR clamping, droplet digital PCR and Sanger for IDH2 status
identification were evaluated and compared in 96 DNA patients’ specimens. Results: In contrast
with Sanger sequencing, our results highlighted the concordance between PNA clamping and digital
PCR. Furthermore, PNA-PCR clamping was able to detect more mutated DNA with respect to Sanger
sequencing that showed several false negatives independently from the allelic frequency. Conclusions:
We found that PNA-PCR clamping and digital PCR identified IDH2 mutations in DNA samples with
comparable results in a percentage significantly higher compared to Sanger sequencing. PNA-PCR
clamping can be used even in laboratories not equipped for sophisticated analyses, decreasing cost
and time for IDH2 characterization.
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1. Introduction
Acute myeloid leukemia (AML) is a malignant neoplasm characterized by a blockade in the
differentiation of hematopoietic stem cells, with consequent abnormal accumulation of immature
myeloid blasts and reduced production of mature blood cells [1]. AML is one of the most frequent
disorders, constituting about 30% of cases of leukemia in adulthood [2]. Its incidence increased
significantly with age, with an average at diagnosis of 65 years [3,4]. Although modern medicine tries
to characterize AML, its prognostic stratification is still based on cytogenetic and on the detection of
known mutations. The development of effective methodologies to identify new targets and to stratify
patients is mandatory, with the goal of allowing each patient to receive a tailored therapy and to predict
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the probability of response. Although the precise prognostic significance of some molecular markers is
still unclear, they might become interesting for the presence of specific drugs that target them: this
is the case of the gene “isocitrate dehydrogenase 2” (IDH2) [5]. The Food and Drug Administration
has recently approved Enasidenib, a specific molecular inhibitor for patients with AML with mutated
IDH2. IDH2 is an enzyme that catalyzes the first oxidative decarboxylation reaction of the isocitrate to
α-ketoglutarate (α-KG) in the tricarboxylic acid cycle. Mutations in the IDH2 gene occur in 8–19%
of patients with AML [6], with high frequencies in older patients. The most frequent mutations of
IDH2, which affect over 95% of IDH2 mutated patients, involve the arginine residues in position
R140 and R172. Mutant proteins acquire the ability to reduce the α-KG to (R)-2-hydroxyglutarate
(2-HG). This oncometabolite competitively inhibits α-KG-dependent epigenetic regulators, including
histone demethylases. Consequently, 2-HG accumulation leads to DNA hypermethylation, blocking
cellular differentiation [7–9]. Furthermore, 2-HG also involves RNA epigenetic modification, especially
N6-methyladenosine (m6A), via FTO [10]. The persistence of IDH2 mutations was observed in about
40% of AML patients in complete remission (CR) or in complete remission with incomplete hematologic
recovery (CRi) and is associated with a greater risk of recurrence [11]. This suggested the use of IDH2
as possible molecular markers for MRD, particularly in the absence of other molecular alterations [12].
For these reasons, it is mandatory to monitor IDH2 mutations to better characterize AML patients.
To evaluate the IDH2 status in AML patients, Sanger sequencing and droplet digital PCR (ddPCR)
are considered useful molecular approaches. Sanger sequencing is the most used method with a
limitation due to its poor limit of detection (−20%), in contrast, ddPCR has recently emerged as a highly
sensitive and accurate technology [13]. Both these methods have the disadvantage of needing expensive
apparatus and reagents. With the purpose of identifying a new molecular technique that is fast and
cheap but with a sensitivity comparable to ddPCR, we developed a novel assay using peptide nucleic
acid (PNA)-PCR clamping to detect IDH2 R140Q and R172K mutations. PNA is a synthetic polymer
analogous to DNA and RNA, with a skeleton characterized by repeating N-(2-aminoethyl)-glycine
units linked by peptide bonds [14]. Unlike primers, PNA probes lack pentose sugar-phosphate groups,
so PNA/DNA binding is stronger than DNA/DNA duplex. In addition, PNA/DNA complex is so
specific that a single base mismatch can destabilize it [15]. Finally, PNA oligomers are not degraded or
recognized by polymerase and therefore cannot be directly used as primers [16]. Our method exploits
the ability of PNA to hybridize very specifically to DNA, without being extended by a polymerase,
consequently suppressing DNA amplification [17–19].
2. Experimental Section
2.1. Patient’s Cohort
After informed consent, 96 DNA was extracted from human bone marrow or peripheral blood of
AML patients (74 at diagnosis and 22 during follow up). DNA was extracted using Maxwell 16 Blood
DNA Purification kit (Promega, Milan, Italy), following the manufacturer’s instructions. Patients were
characterized at the cytogenetic level by conventional karyotyping and screened by Real-Time PCR for
the presence of the most frequent fusion transcripts, as previously described [20]. NPM1 [21] and FLT3
ITD [22] mutations were screened and WT1 mRNA levels were also evaluated [23]. Patients younger
than 60 years were treated following standard protocols established by the GIMEMA Cooperative
Group for the treatment of adult patients with AML [17]. Elderly and unfit patients were treated as
previously described [17]. The study was approved by the local ethics committee of San Luigi Hospital,
Orbassano, Turin (Number of approval 201/2014).
2.2. Cloning PCR Controls with pGEM®—T Easy Vector
Plasmids used as positive controls were generated amplifying IDH2 R140Q and R172K from
mutated AML patients with the following primers: forward 5′-AGACTCCAGAGCCCACACAT-3′ and
reverse 5′-CTCGTCGGTGTTGTACATGC-3′. Subsequently, the PCRs were purified by QIAquick Gel
J. Clin. Med. 2020, 9, 271 3 of 11
Extraction Kit (Qiagen, Hildem, Germany) and cloned in pGEM-T Easy Vector (Promega, Milan, Italy).
The sequences were verified by the capillary Sanger sequence method. All reactions were performed
following the manufacturer’s instructions.
2.3. Sanger Sequencing for IDH2mut Detection
To perform Sanger sequencing, IDH2 was amplified from DNA (50 ng) of AML patients and
analyzed by sequencing with BigDye terminator v3.1 (Applied Biosystem, Foster City, CA, USA) and
capillary electrophoresis on ABI PRISM 3130XL (Applied Biosystem, Foster City, CA, USA), using
primers described by Marcucci et al. [24]. Out of 96 patients’ samples, 91 were efficiently sequenced,
whereas for 5 samples, the sequences failed probably due to the quality of DNA. The sensitivity of the
method was previously estimated by serial dilutions experiments to be approximately 15–20% [25].
2.4. ddPCR for IDH2mut Detection
Detection of IDH2 R140Q and R172K (#dHsaMDV2010057 and #dHsaMDV2010059, respectively,
Biorad, Hercules, CA, USA) was performed by QX200 ddPCR system (Biorad, Hercules, CA, USA).
For IDH2mutdetection, 100 ng of each patient’s DNA and 0.2 pg of control plasmids were used. All reactions
were performed following the manufacturer’s instructions and generated evaluable data. Results were
expressed as a percentage of mutated allele compared to wild type (WT) [(IDH2mut/IDH2) ×100].
2.5. PNA Directed PCR Clamping for IDH2mut Detection
The method for the detection of IDH2 mutations by PNA-PCR clamping forecasted two PCR to
detect IDH2 R140Q and R172K, respectively. Primers and PNA probes for IDH2 amplification were
designed on DNA sequences NG_023302.1. DNA of patients (250 ng) were used to amplify a small
area of IDH2. PCR amplification for each mutation was carried out in duplicate in the presence (PNA+)
or in the absence (PNA−) of PNA probes. Primers and PNA probes sequences are listed in Table 1.
Table 1. Primers and PNA probes sequences for PNA-PCR clamping.
Primer/PNA Probe Sequence 5′-3′
IDH2 forward CCAATGGAACTATCCAGAACATC
IDH2 R140Q reverse CTCGTCGGTGTTGTACATGC
IDH2 R172K reverse TATATCGCCATGGGCGTGCTT
IDH2 R140Q PNA CTATCCGGAACATCCT
IDH2 R172K PNA TGGGCGTGCCTGCCAAT
PNA-PCR clamping for IDH2 R140Q: reaction volume was 50 µL and the final concentrations of
the reagents were as follow: MgCl2 [2.5 µM], 10X PCR Buffer [1X], dNTPs [200 nM], AmpliTaq 1U,
Primers [100 nM each], PNA probe [300 nM]. PCR conditions were as follows: 95 ◦C 2 min, (95 ◦C 15 s,
55 ◦C 15 s, 68 ◦C 30 s) for 40 cycles, 68 ◦C 5 min. PNA PCR clamping for IDH2 R172K: reaction volume
was 50 µL and the final concentrations of the reagents were as follows: MgCl2 [2.5 µM], 10× PCR Buffer
[1×], dNTPs [200 nM], AmpliTaq 1U, Primers [200 nM each], PNA probe [800 nM]. PCR conditions
were as follows: 95 ◦C 2 min, (95 ◦C 30 s, 58 ◦C 20 s, 68 ◦C 30 s) for 40 cycles, 68 ◦C 5 min. 1 pg of
each plasmid was used as control in PCR amplification. After PCR, 10 µL of each amplicon were
loaded on 2% Agarose-TBE 1× gel with 5 µg/mL Ethidium Bromide (EtBr) and run at 120 V for 30 min.
The electrophoretic runs were acquired with the ChemiDoc XRS+ (Biorad, Hercules, CA, USA) and
analyzed with the Image Lab software 4.0.1 (Biorad, Hercules, CA, USA). All reactions for each IDH2
mutation generated evaluable data that was compared to the other methodologies.
2.6. Statistical Analysis
Diagnostic test equivalency was checked with the McNemar statistical test. Diagnostic test
valuation was calculated with MedCalc software (MedCalc, Osten, Belgium). Sensitivity is defined as
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probability that a test result will be positive when the disease is present (true positive rate); specificity is
probability that a test result will be negative when the disease is not present (true negative rate); positive
likelihood ratio (LR+) is ratio between the probability of a positive test result given the presence of the
disease and the probability of a positive test result given the absence of the disease; negative likelihood
ratio (LR−) is the ratio between the probability of a negative test result given the presence of the disease
and the probability of a negative test result given the absence of the disease; positive predictive value
(PV+) is probability that the disease is present when the test is positive; negative predictive value (PV−)
is probability that the disease is not present when the test is negative and accuracy is defined as overall
probability that a patient will be correctly classified. Baseline characteristics were investigated using
Fisher’s exact test for categorical and unpaired t-test for continuous variables. Statistical analyses were
performed using GraphPad Prism 6 and R statistical software. All the analyses with a p-value minor or
equal to 0.05 were indicated as significant.
3. Results
3.1. IDH2 R140Q and R172K Detection by PNA-PCR Clamping
The method described forecasts an overlay between the sequences of PNA probes and the
competitor primers IDH2 forward and IDH2 R172K reverse (Table 1) respectively for the detection
of R140Q and R172K mutations, thus leading to a direct competition towards complementary DNA.
In the case of IDHwt, a perfect matching occurs between PNA (designed on reference sequence) and
DNA, so the PNA-template hybridization is favored, while DNA amplification results suppressed.
Contrariwise, a non-perfect matching (as in the case of IDH2mut) promotes the hybridization between
template and primer competitors, allowing a specific amplification (Figure 1).
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 4 of 11 
 
Diagnostic test equivalency was checked with the McNemar statistical test. Diagnostic test 
valuation was calculated with MedCalc software (MedCalc, Osten, Belgium). Sensitivity is defined 
as probability that a test result will be positive when the disease is present (true positive rate); 
specificity is probability that a test result will be negative when the disease is not present (true 
negative rate); positive likelihood ratio (LR+) is ratio between the probability of a positive test result 
given the presence of the disease and the probability of a positive test result given the absence of the 
disease; negative likelihood ratio (LR−) is the ratio between the probability of a negative test result 
given the presence of the disease and the probability of a negative test result given the absence of the 
disease; positive predictive value (PV+) is probability that the disease is present when the test is 
p sitive; negative predictive value (PV−) is probability that the dis ase is not present when the test is 
negative and ccuracy is defined as overall probability that a p tient will be correctly classified. 
Baseline characteristics were investigated using Fishe ’s exact test for categorical and unpaired t-test 
for continuous v riables. Statistical analyses were performed using GraphPad Prism 6 and R 
statistical software. All the analyses with a p-value minor or equal to 0.05 were indicated as 
significant. 
3. Results 
3.1. IDH2 R140Q and R172K Detection by PNA-PCR Clamping 
The method described forec sts an overlay betwe n the sequenc  of PNA probes and the 
competitor primers IDH2 forward and IDH2 R172K reverse (Table 1) respectively for the detection of 
R140Q and R172K mutations, thus leading to a direct competition towards complementary DNA. In 
the case of IDHwt, a perfect matching occurs between PNA (designed on reference sequence) and 
DNA, so the PNA-template hybridization is favored, while DNA amplification results suppressed. 
Contrariwise, a non-perfect matching (as in the case of IDH2mut) promotes the hybridization between 
template and primer competitors, allowing a specific amplification (Figure 1). 
 
Figure 1. PNA-PCR clamping experimental design. Amplification of IDH2 was performed in presence 
of PNA probe (light blue), designed on the WT sequence, and Primer competitor (purple), designed 
on the mutated sequence. In these conditions, the PCR of the WT sequence is inhibited by the inability 
of the primer competitor to detach the perfect hybridization PNA/DNA. In contrast, in the presence 
of IDH2mut, PNA/DNA duplex is highly destabilized by the Primer competitor, allowing a strong 
amplification of the target sequence. 
The amplifications have been carried out in duplicate, in presence (PNA+) or absence (PNA−) of 
the PNA probes, for both IDH2 R140Q and R172K reactions. The result was interpreted by reading 
Figure 1. PNA-PCR clamping experimental design. Amplification of IDH2 was performed in presence
of PNA probe (light blue), designed on the WT sequence, and Primer competitor (purple), designed on
the mutated sequence. In these conditions, the PCR of the WT sequence is inhibited by the inability
of the primer competitor to detach the perfect hybridization PNA/DNA. In contrast, in the presence
of IDH2mut, PNA/DNA duplex is highly destabilized by the Primer competitor, allowing a strong
amplification of the target sequence.
The amplifications have been carried out in duplicate, in presence (PNA+) or absence (PNA−) of
the PNA probes, for both IDH2 R140Q and R172K reactions. The result was interpreted by reading the
double loading for each patient: IDH2wt if there was no amplification in (PNA+) and amplification
in (PNA−); IDH2mut if there was amplification in both (PNA+) and (PNA−) mixtures. Each DNA
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sample has been screened for both IDH2 R140Q and R172K with two different PCR (Figure 2A).
The detection limit of the assays has been assessed by mixing, at a different ratio, pGEMT-IDH2mut
and pGEMT-IDH2wt. Dilutions were as follows: 100, 50, 30, 20, 10, 5, 1 and 0.5% pGEMT-IDH2mut vs.
pGEMT-IDH2wt template. The method displayed a low detection limit, allowing us to identify an
amount of IDH2 R140Q template as low as 1% and IDH2 R172K template as low as 0.5%, which cannot
be identified by Sanger sequencing (Figure 2B).
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Figure 2. Electrophoretic runs of PCR reactions: 10µL of each amplicon were loaded on 2% Agarose-TBE
1× gel with 5 µg/mL EtBr and run at 120 V for 30 min. PNA-PCR clamping for IDH2 R140Q and R172K
carried out in absence (PNA−) or in presence (PNA+) of the PNA probe. (A) PNA-PCR clamping in
DNA from AML samples and control plasmid. The results, read in duplicate, were: IDH2 WT, if there
was no amplification in (PNA+) and amplification in (PNA−) in both the PCR (for R140Q and R172K
reaction); IDH2 R140Q, if there was amplification in both (PNA+) and (P A−) in R140Q reaction and
there was no amplification in (PNA+) and amplification in (PNA−) in R172K reaction; IDH2 R172K, if
there was amplification in both (PNA+) and (PNA−) in R172K reaction and there was no amplification
in (PNA+) and amplification in (PNA−) in R140Q reaction. (B) PNA-PCR clamping sensitivity assessed
mixing at different ratio IDH2mut and IDH2wt te plate in the same PCR reaction. Dilutions were as
follows: 100, 50, 30, 20, 10, 5, 1 and 0.5% IDH2mut (R140Q or R172K) all br ught to 100% with the
respective amount of IDH2wt template. The p rcentage of the mutated template is in icated. Red
boxes highlight the limit of detection of the PNA-PCR clamping method for e ch mutation in the study.
3.2. Comparison of Sanger Sequencing, PNA-PCR Clamping and ddPCR for the IDH2mut Detection
Due to the high sensitivity of ddPCR [13], confirmed also in our hands, we considered ddPCR
as the reference technique, and we compared the performances of Sanger sequencing and PNA-PCR
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clamping methods. PNA-PCR clamping, Sanger Sequencing, and the ddPCR were utilized to blind-test
96 DNA from AML patients (74 at diagnosis and 22 during follow-up) for IDH2 mutations. Since
the IDH2 mutations, R140Q and R172K include more than 95% of all IDH2 mutations in AML,
we subsequently considered the results as a whole, without distinguishing between them. In particular,
ddPCR and Sanger identified congruently 70 negative and 14 positive patients. By contrast, seven
patients identified as positive by ddPCR were missed in Sanger analysis. Although the two techniques
are in agreement in 92.3% of analysis, they are significantly different according to McNemar’s test that
checked the disagreements between two matched cases (p = 0.02 for Sanger vs. ddPCR) (Figure 3A).
As shown in the agreement plot (Figure 3B), PNA clamping and ddPCR were in accordance with 96.9%
of the analysis with only three patients differently detected by the PNA clamping test. The agreement
between ddPCR and PNA-PCR clamping was confirmed also by McNemar’s test that does not highlight
differences in the proportion of disagreement data (p > 0.05).
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Figure 3. Agreement charts for comparing IDH2 status evaluation techniques. In agreement plots,
the black blocks indicate the accordance of results for each method with respect to the ddPCR, selected
as a calibrator for the analysis. ddPCR and PNA-PCR clamping (B) had a greater agreement with
respect to ddPCR and Sanger sequencing (A), as also suggested by the shorter segment of the red 45◦
diagonal line not included in the black blocks. The 2 × 2 tables alongside underline the differences of
each methodology with respect to ddPCR.
Figure 4 shows an example of three DNA from AML patients tested with the three different
techniques: PNA-PCR clamping (Figure 4A), Sanger sequencing (Figure 4B) and ddPCR (Figure 4C).
The example shows that all techniques correctly identified IDH2 status for patient #1 and #2, wild type
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and mutated in heterozygosis (47.4% of mutation quantified by ddPCR), respectively. By contrast,
patient #3 resulted in IDH2 mutated by ddPCR and PNA-PCR clamping, while Sanger sequencing
failed to identify the IDH2 mutation (16.4% of mutation quantified by ddPCR).
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of the analysis. Indeed, we evaluated the accuracy of the tests compared to ddPCR, including the
sensitivity and specificity, LR+ and LR−, PV+ and PV−. Results indicated that, although specificity
and PV− resulted equal for both methods (100%), PNA-PCR clamping was ore sensible and accurate
than Sanger sequencing (87.5 vs. 66.7% and 96.9 vs. 92.3%, respectively). Further, it showed a better
LR− and PV−with respect to the Sanger method (0.12 vs. 0.33 and 96.0 vs. 90.9%, respectively).
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Figure 5. IDH2 status evaluation techniques detection limits and results agreement. The graphs indicate
all the variant allelic frequency (VAF) of IDH2 mutations identified in AML patients with ddPCR and
sorted from 0% (WT) to 50% mutated (heterozygous). ddPCR identified IDH2 mutant already by 0.6%
of VAF, while PNA-PCR clamping failed to identify positive patients under the 1% of VAF (zoom of
this region is showed in the dotted circle). Contrariwise, the discriminatory ability of Sanger sequence
was randomly distributed in all ranges of IDH2 mutation percentage, decreasing the robustness of the
analysis. Negative (−), positive (+) and false negative (*).
3.3. Prevalence of I 2 ut in L Sa ples
ccording to previously published data [26], ddPCR detected IDH2mut in 12 out of 74 patients at
diagnosis (16.2% of the samples), PNA-PCR clamping in 11 (14.8%) and Sanger sequencing in only
nine (12.1 ). e co pared the baseline characteristics of patients carrying the I 2 ut and I 2 t
patients. e did not find any significant correlation between IDH2mut and age, sex, molecular lesions,
and WT1 expression at diagnosis. In accordance with published data, the IDH2 R140Q and R172K
mutations were significantly associated with a normal karyotype (p = 0.04) [27]. In particular, only one
out of 12 mutated patients showed MLL rearrangement between exon 10 and exon 2. Three patients
were treated with Enasidenib, two of them became negative for IDH2 mutation by PNA-PCR clamping
and with 0.6% of residual mutation by ddPCR, one remained positive by both methods (43% by ddPCR).
One patient was treated with chemotherapy and the utation was etectable during follow-up by
PNA-PCR clamping and ddP (from 45% at diagnosis to 38.5 after induction chemotherapy). Finally,
one patient was treated with azacitidine and remained stable from 45% to 47% by ddPCR.
4. Discussion
AML is a heterogeneous hematological disease, characterized by several karyotypic and molecular
alterations. Among these, mutations in IDH2 gene are found in 8–19% of AML patients [26].
The prognostic significance of IDH2 mutation at diagnosis is not completely clear and even less clear is
the persistence of IDH2 mutation after chemotherapy, therefore the role of IDH2 mutation as a marker of
MRD needs investigation [12]. In clinical practice, the evaluation of IDH2 mutations allows a targeted
therapeutic choice, based on a specific IDH2 selective inhibitor (Enasidenib) [28,29]. Frequently the
mutated clones at diagnosis are small with a variant allele frequency (VAF) less than 20%, the limit
of detection of Sanger sequencing. Furthermore, the identification of residual clones after therapy
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requires highly sensitive techniques. In this study, we compared a new technology that is sensible, fast,
and cheap to identify and monitor IDH2 mutations based on PNA-PCR clamping and we compared this
technique with droplet digital PCR and Sanger sequencing. In our study, PNA-PCR clamping rapidly
identified IDH2 R140Q and R172K mutations in DNA samples with results comparable to ddPCR.
In the last years, the PNA-PCR clamping technique showed high efficiency, sensitivity, and specificity
and its results were faster and cheaper compared with Sanger sequencing [17–19]. We evaluated
the IDH2 status in 96 DNA samples from AML patients with the three methods and we observed
that PNA-PCR clamping was in accordance with ddPCR results, in contrast, there was a significant
disagreement between Sanger sequencing and the ddPCR results. PNA-PCR clamping showed a limit
of detection of about 1% of mutations that was extrapolated in vitro by serial dilutions of mutated
plasmids and subsequently confirmed in DNA samples from AML patients. This limit of detection is
markedly lower compared to the Sanger method, estimated in the literature to be 15–20% [25]. Further,
in our analysis, Sanger sequencing showed some cases of false-negative not correlated with VAF. These
sequencing results were probably affected by several external conditions, for example, the quality
of DNA. Interestingly, in the same samples, the mutations were detected by PNA-PCR clamping in
accordance with ddPCR. This data suggested that PNA-PCR clamping could be an effective method to
monitor IDH2 mutations especially during follow up, where the allele frequency is often below the
limit of detection of Sanger sequencing.
Possible disadvantages of our technique could be represented by the fact that PNA-PCR clamping
allows only a targeted analysis thus identifying specific mutations defined a priori and it is not
able to distinguish a mixed population that often characterizes leukemia. However, these are also
limits of Sanger sequencing and ddPCR. This limitation could be overcome only by expensive and
time-consuming next-generation sequencing. Considering the accuracy and sensitivity of PNA-PCR
clamping, close to ddPCR, its rapidity and its cost, it could be used to early diagnose the presence of
IDH2 mutations, allowing patients to begin a targeted therapy in a reasonable time interval.
5. Conclusions
In conclusion, considering the relevance of IDH2 mutation as a diagnostic and prognostic marker,
PNA-PCR clamping could be considered a valid alternative to Sanger sequencing in routine tests and
to follow MRD. Further, our assay could be used even in laboratories not equipped for sophisticated
analyses, resulting in a faster and cheaper method than the Sanger method and ddPCR, allowing a
decrease in the cost and time for advances in molecular investigation and to correctly characterize
AML IDH2 mutated patients.
6. Patents
The PNA-PCR clamping assay for IDH2 mutations has been patented by VR, JP, DC and by the
University of Turin (Italian patent number 102016000042586).
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